https://www.pharmaceutical-technology.com/data-insights/azd-5462-astrazeneca-congestive-heart-failure-heart-failure-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-184488&utm_campaign=recommended-articles-pi
AZD-5462 is under clinical development by AstraZeneca and currently in Phase II for Congestive Heart Failure (Heart Failure).
congestive heart failureazdastrazeneca
https://www.pharmaceutical-technology.com/data-insights/azd-9829-astrazeneca-refractory-acute-myeloid-leukemia-likelihood-of-approval/
AZD-9829 is under clinical development by AstraZeneca and currently in Phase II for Refractory Acute Myeloid Leukemia.
acute myeloid leukemiaazdastrazenecarefractorylikelihood
https://www.pharmaceutical-technology.com/data-insights/azd-3470-astrazeneca-solid-tumor-likelihood-of-approval/
AZD-3470 is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor.
solid tumorazdastrazenecalikelihoodapproval
https://www.pharmaceutical-technology.com/data-insights/azd-5492-astrazeneca-follicular-lymphoma-likelihood-of-approval/
AZD-5492 is under clinical development by AstraZeneca and currently in Phase II for Follicular Lymphoma.
follicular lymphomaazdastrazenecalikelihoodapproval
https://www.pharmaceutical-technology.com/data-insights/azd-5863-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/
AZD-5863 is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma.
azdastrazenecapancreaticadenocarcinomalikelihood